Acute Kidney Injury Biomarkers - Needs, Present Status, and Future Promise.
作者信息
Zhou Hua, Hewitt Stephen M, Yuen Peter S T, Star Robert A
机构信息
Renal Diagnostics and Therapeutics Unit, NIDDK, National Institutes of Health.
出版信息
Nephrol Self Assess Program. 2006 Mar;5(2):63-71.
Abstract
摘要
相似文献
1
Acute Kidney Injury Biomarkers - Needs, Present Status, and Future Promise.急性肾损伤生物标志物——需求、现状与未来前景
Nephrol Self Assess Program. 2006 Mar;5(2):63-71.
2
Biomarkers for the diagnosis of acute kidney injury.用于诊断急性肾损伤的生物标志物。
Nephron Clin Pract. 2008;109(4):c192-7. doi: 10.1159/000142928. Epub 2008 Sep 18.
3
Tubular proteinuria in acute kidney injury: a critical evaluation of current status and future promise.急性肾损伤中的管状蛋白尿：对当前状况和未来前景的批判性评估。
Ann Clin Biochem. 2010 Jul;47(Pt 4):301-12. doi: 10.1258/acb.2010.010076. Epub 2010 May 28.
4
Biomarkers for the diagnosis of acute kidney injury.用于诊断急性肾损伤的生物标志物。
Curr Opin Nephrol Hypertens. 2007 Nov;16(6):557-64. doi: 10.1097/MNH.0b013e3282f08745.
5
Proteomics in acute kidney injury--current status and future promise.急性肾损伤中的蛋白质组学——现状与未来展望
Pediatr Nephrol. 2014 Feb;29(2):163-71. doi: 10.1007/s00467-013-2415-x. Epub 2013 Apr 18.
6
Current Status of Novel Biomarkers for the Diagnosis of Acute Kidney Injury: A Historical Perspective.急性肾损伤诊断新生物标志物的现状：历史视角
J Intensive Care Med. 2020 May;35(5):415-424. doi: 10.1177/0885066618824531. Epub 2019 Jan 17.
7
Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis.用于评估重症监护收治患者急性肾损伤的生物标志物：系统评价和成本效益分析。
Health Technol Assess. 2022 Jan;26(7):1-286. doi: 10.3310/UGEZ4120.
8
Biomarkers of renal recovery after acute kidney injury.急性肾损伤后肾脏恢复的生物标志物。
Rev Bras Ter Intensiva. 2017 Jul-Sep;29(3):373-381. doi: 10.5935/0103-507X.20170051.
9
New biomarkers of acute kidney injury: promise for the future but beware the lure of novelty.急性肾损伤的新型生物标志物：前景可期，但谨防新奇事物的诱惑。
Crit Care Med. 2009 Feb;37(2):766-7. doi: 10.1097/CCM.0b013e318194dfd0.
10
Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy.顺铂化疗患者肾损伤的尿蛋白生物标志物。
Exp Biol Med (Maywood). 2018 Feb;243(3):272-282. doi: 10.1177/1535370217745302. Epub 2017 Dec 12.
引用本文的文献
1
Population Pharmacokinetic/Toxicodynamic Model for Polymyxin B in Critically Ill Patients to Identify the Risk of Nephrotoxicity.危重症患者多粘菌素B的群体药代动力学/药效学模型以识别肾毒性风险
Clin Pharmacol Ther. 2025 Jun 16. doi: 10.1002/cpt.3729.
2
The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review.新型生物标志物在急性肾损伤早期检测与管理中的效能：一项系统综述。
PLoS One. 2025 Jan 29;20(1):e0311755. doi: 10.1371/journal.pone.0311755. eCollection 2025.
3
Gold Nanoparticle Transport in the Injured Kidneys with Elevated Renal Function Biomarkers.肾功能生物标志物升高的损伤肾脏中的金纳米颗粒转运
Adv Mater. 2024 Sep;36(36):e2402479. doi: 10.1002/adma.202402479. Epub 2024 Jul 29.
4
Molecular Phenotyping of Patients with Sepsis and Kidney Injury and Differential Response to Fluid Resuscitation.脓毒症合并肾损伤患者的分子表型分析及对液体复苏的不同反应
Res Sq. 2024 Jul 2:rs.3.rs-4523416. doi: 10.21203/rs.3.rs-4523416/v1.
5
Cystatin C Outperforms Creatinine in Predicting Cefepime Clearance in Pediatric Stem Cell Transplant Recipients.胱抑素C在预测儿科干细胞移植受者头孢吡肟清除率方面优于肌酐。
Transplant Cell Ther. 2024 Jun;30(6):614.e1-614.e11. doi: 10.1016/j.jtct.2024.03.021. Epub 2024 Mar 22.
6
Use of Donor-derived Cell-free DNA to Inform Tapering of Immunosuppression Therapy in Kidney Transplant Recipients: An Observational Study.利用供体来源的游离DNA指导肾移植受者免疫抑制治疗的减药：一项观察性研究。
Transplant Direct. 2024 Mar 12;10(4):e1610. doi: 10.1097/TXD.0000000000001610. eCollection 2024 Apr.
7
Clinical courses of acute kidney injury in hospitalized patients: a multistate analysis.住院患者急性肾损伤的临床病程：一项多州分析。
Sci Rep. 2023 Oct 18;13(1):17781. doi: 10.1038/s41598-023-45006-5.
8
Adherence to Established Blood Pressure Targets and Associated Complications in Patients Presenting with Acute Intracerebral Hemorrhage.急性脑出血患者血压目标达标与相关并发症。
Neurocrit Care. 2023 Oct;39(2):378-385. doi: 10.1007/s12028-023-01679-4. Epub 2023 Feb 14.
9
In-Hospital Prescription Checking System for Hospitalized Patients with Decreased Glomerular Filtration Rate.住院患者肾小球滤过率降低的住院医嘱审核系统。
Kidney360. 2022 Jul 8;3(10):1730-1737. doi: 10.34067/KID.0001552022. eCollection 2022 Oct 27.
10
Emerging roles for AQP in mammalian extracellular vesicles.AQP 在哺乳动物细胞外囊泡中的新兴作用。
Biochim Biophys Acta Biomembr. 2022 Mar 1;1864(3):183826. doi: 10.1016/j.bbamem.2021.183826. Epub 2021 Nov 27.
本文引用的文献
1
Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation.尿中性粒细胞明胶酶相关脂质运载蛋白（NGAL）和白细胞介素-18（IL-18）是肾移植后移植肾功能延迟的预测生物标志物。
Am J Transplant. 2006 Jul;6(7):1639-45. doi: 10.1111/j.1600-6143.2006.01352.x.
2
Acute kidney injury, mortality, length of stay, and costs in hospitalized patients.住院患者的急性肾损伤、死亡率、住院时间及费用
J Am Soc Nephrol. 2005 Nov;16(11):3365-70. doi: 10.1681/ASN.2004090740. Epub 2005 Sep 21.
3
Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit.尿白细胞介素-18是急性肾损伤的早期诊断标志物，并可预测重症监护病房的死亡率。
J Am Soc Nephrol. 2005 Oct;16(10):3046-52. doi: 10.1681/ASN.2005030236. Epub 2005 Sep 7.
4
Translational crossroads for biomarkers.生物标志物的转化交叉点
Clin Cancer Res. 2005 Sep 1;11(17):6103-8. doi: 10.1158/1078-0432.CCR-04-2213.
5
Serum cystatin C--a superior marker of rapidly reduced glomerular filtration after uninephrectomy in kidney donors compared to creatinine.血清胱抑素C——与肌酐相比，是肾供体单侧肾切除术后肾小球滤过率快速降低的更优标志物。
Clin Nephrol. 2005 Jul;64(1):41-6. doi: 10.5414/cnp64041.
6
Improved estimation of GFR by serum cystatin C in patients undergoing cardiac catheterization.通过血清胱抑素C改善对接受心导管插入术患者的肾小球滤过率估计。
Int J Cardiol. 2005 Jul 10;102(2):173-8. doi: 10.1016/j.ijcard.2004.04.009.
7
Cystatin C and the risk of death and cardiovascular events among elderly persons.胱抑素C与老年人的死亡风险和心血管事件
N Engl J Med. 2005 May 19;352(20):2049-60. doi: 10.1056/NEJMoa043161.
8
Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery.中性粒细胞明胶酶相关脂质运载蛋白（NGAL）作为心脏手术后急性肾损伤的生物标志物。
Lancet. 2005;365(9466):1231-8. doi: 10.1016/S0140-6736(05)74811-X.
9
Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma.人肾损伤分子-1是肾细胞癌的一种组织和尿液肿瘤标志物。
J Am Soc Nephrol. 2005 Apr;16(4):1126-34. doi: 10.1681/ASN.2004070530. Epub 2005 Mar 2.
10
Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury.脂质运载蛋白-铁载体-铁复合物的内吞递送可使肾脏免受缺血再灌注损伤。
J Clin Invest. 2005 Mar;115(3):610-21. doi: 10.1172/JCI23056.
Zotero 插件